Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men
- PMID: 20972372
- PMCID: PMC2952086
- DOI: 10.4161/oxim.3.4.12734
Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men
Abstract
Advanced glycation end products (AGEs) are involved in cardiovascular disease. Low testosterone level is associated with increased risks of cardiometabolic disorders as well. However, which anthropometric and metabolic variables, including AGEs, are independently correlated with low testosterone is largely unknown. In this study, we investigated whether high serum level of AGEs is one of the independent determinants of low testosterone in non-diabetic men. One hundred thirteen non-diabetic men who did not receive any drugs for hypertension and dyslipidemia underwent a complete history and physical examination, determination of blood chemistries, including serum AGEs and testosterone. Univariate analysis showed that testosterone levels were associated with waist circumference (inversely), diastolic blood pressure (BP) (inversely), mean BP (inversely), triglycerides (inversely), HDL-cholesterol, fasting plasma glucose (inversely), fasting insulin (inversely), homeostasis model assessment of insulin resistance (HOMA-IR) (inversely), AGEs (inversely) and uric acid (inversely). By the use of multiple stepwise regression analyses, HOMA-IR (p = 0.005) and triglycerides levels (p < 0.05) remained significant and were independently related to testosterone levels (R(2) = 0.168). HOMA-IR index was one of the independent determinants of serum levels of AGEs as well. The present study demonstrated for the first time that HOMA-IR was independently associated with high serum levels of AGEs and low testosterone in non-diabetic men. Insulin resistance could link elevation of AGEs to testosterone deficiency in non-diabetic men.
Keywords: AGEs; insulin resistance; testosterone.
Figures

Similar articles
-
Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs).Oxid Med Cell Longev. 2010 Sep-Oct;3(5):304-7. doi: 10.4161/oxim.3.5.13069. Epub 2010 Sep 1. Oxid Med Cell Longev. 2010. PMID: 21150335 Free PMC article.
-
Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects.Cardiovasc Ther. 2012 Feb;30(1):42-8. doi: 10.1111/j.1755-5922.2010.00177.x. Epub 2010 Jul 7. Cardiovasc Ther. 2012. PMID: 20626403
-
Serum advanced glycation end products (AGEs) are associated with insulin resistance.Diabetes Metab Res Rev. 2011 Jul;27(5):488-92. doi: 10.1002/dmrr.1188. Diabetes Metab Res Rev. 2011. PMID: 21337488
-
High Plasmatic Levels of Advanced Glycation End Products are Associated with Metabolic Alterations and Insulin Resistance in Preeclamptic Women.Curr Mol Med. 2020;20(9):751-759. doi: 10.2174/1566524020666200220141414. Curr Mol Med. 2020. PMID: 32077826
-
Features of the metabolic syndrome in late adolescence are associated with impaired testicular function at 20 years of age.Hum Reprod. 2019 Mar 1;34(3):389-402. doi: 10.1093/humrep/dey371. Hum Reprod. 2019. PMID: 30576537
Cited by
-
Effect of gamma-mangostin on testosterone levels in Leydig cell culture of Sprague-Dawley rat induced by advanced glycation end products: a preliminary study.BMC Proc. 2019 Dec 16;13(Suppl 11):12. doi: 10.1186/s12919-019-0173-x. eCollection 2019. BMC Proc. 2019. PMID: 31890005 Free PMC article.
-
Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.Clin Cardiol. 2011 Apr;34(4):261-5. doi: 10.1002/clc.20855. Epub 2011 Feb 1. Clin Cardiol. 2011. PMID: 21432858 Free PMC article. Clinical Trial.
-
Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension.Oxid Med Cell Longev. 2010 Sep-Oct;3(5):342-6. doi: 10.4161/oxim.3.5.13199. Epub 2010 Sep 1. Oxid Med Cell Longev. 2010. PMID: 21150340 Free PMC article.
-
Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs).Oxid Med Cell Longev. 2010 Sep-Oct;3(5):304-7. doi: 10.4161/oxim.3.5.13069. Epub 2010 Sep 1. Oxid Med Cell Longev. 2010. PMID: 21150335 Free PMC article.
-
Pericytopathy: oxidative stress and impaired cellular longevity in the pancreas and skeletal muscle in metabolic syndrome and type 2 diabetes.Oxid Med Cell Longev. 2010 Sep-Oct;3(5):290-303. doi: 10.4161/oxim.3.5.13653. Epub 2010 Sep 1. Oxid Med Cell Longev. 2010. PMID: 21150342 Free PMC article. Review.
References
-
- Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic and clinical implications for diabetes and aging. Lab Invest. 1994;70:138–151. - PubMed
-
- Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med. 1995;46:223–234. - PubMed
-
- Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11:2279–2299. - PubMed
-
- Yamagishi S, Matsui T. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs) Curr Drug Targets. 2010;11:875–881. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources